Print

GlaxoSmithKline (GSK)'s Contract Manufacturing Delays Cause Shortage of Restless Leg Treatment  
4/18/2013 8:33:00 AM

The FDA announced a shortage of Horizant (gabapentin enacarbil; GlaxoSmithKline) 600mg extended-release tablets. Horizant is a prodrug of gabapentin that is indicated for postherpetic neuralgia and for moderate-to-severe primary restless legs syndrome in adults. GlaxoSmithKline is currently experiencing a backorder situation. XenoPort will assume manufacturing and commercialization of Horizant from May 1, 2013. XenoPort anticipates the Horizant shortage to extend into June 2013.
//-->